Literature DB >> 28597485

Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography.

F M A van Hout1,2, I J Bontekoe3, L A E de Laleijne3, J-L Kerkhoffs1, D de Korte3, J Eikenboom4, J G van der Bom1,2, P F van der Meer1,3.   

Abstract

BACKGROUND AND OBJECTIVES: There are concerns about the haemostatic function of platelets stored in platelet additive solution (PAS). Aim of this study was to compare the haemostatic function of PAS-C-platelets to plasma-platelets in reconstituted whole blood.
MATERIALS AND METHODS: In our experiment, whole blood was reconstituted with red blood cells, solvent-detergent (SD) plasma and either PAS-C-platelets or plasma-platelets (n = 7) in a physiological ratio. On storage days 2, 5, 8 and 13, the agonist-induced aggregation (multiple electrode aggregometry), clot formation (thromboelastography) and agonist-induced CD62P responsiveness (flow cytometry) were measured.
RESULTS: Samples with PAS-C-platelets showed significantly lower aggregation than plasma-platelets when induced with adenosine diphosphate, -6 U (95% confidence interval: -8; -4) or thrombin receptor-activating protein, -15 U (-19; -10). Also when activated with collagen and ristocetin, the PAS-C-platelets showed less aggregation, although not statistically significant. All samples with PAS-C-platelets showed significantly lower agonist-induced CD62P responsiveness than samples with plasma-platelets. However, there was no difference regarding all TEG parameters.
CONCLUSION: Our findings demonstrate that the function - aggregation and CD62P responsiveness - of PAS-C-platelets in reconstituted whole blood is inferior to that of plasma-platelets, which may have implications in the setting of massive transfusions.
© 2017 International Society of Blood Transfusion.

Entities:  

Keywords:  CD62P expression; haemostatic function; multiple electrode aggregometry; platelet additive solution; thromboelastography

Mesh:

Substances:

Year:  2017        PMID: 28597485     DOI: 10.1111/vox.12534

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

Review 1.  Platelet Additive Solutions: A Review of the Latest Developments and Their Clinical Implications.

Authors:  Pieter F van der Meer; Dirk de Korte
Journal:  Transfus Med Hemother       Date:  2018-03-09       Impact factor: 3.747

2.  Haemostatic profile of riboflavin-treated apheresis platelet concentrates.

Authors:  Eleni Petrou; Georgios K Nikolopoulos; Anastasios G Kriebardis; Katerina Pantavou; Electra Loukopoulou; Andreas G Tsantes; Hara T Georgatzakou; Eirini Maratou; Evdoxia Rapti; Sofia Mellou; Styliani Kokoris; Argyri Gialeraki; Argirios E Tsantes
Journal:  Blood Transfus       Date:  2021-05-21       Impact factor: 5.752

3.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Authors:  Frédéric Garban; Audrey Guyard; Helene Labussière; Claude-Eric Bulabois; Tony Marchand; Christiane Mounier; Denis Caillot; Jacques-Olivier Bay; Valérie Coiteux; Aline Schmidt-Tanguy; Catherine Le Niger; Christine Robin; Patrick Ladaique; Simona Lapusan; Eric Deconinck; Carole Rolland; Alison M Foote; Anne François; Chantal Jacquot; René Tardivel; Pierre Tiberghien; Jean-Luc Bosson
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.